Examining risk behavior and syringe coverage among people who inject drugs accessing a syringe services program: A latent class analysis.
Drug Policy
HCV
HIV prevention
Substance use
Syringe Services Program
Journal
The International journal on drug policy
ISSN: 1873-4758
Titre abrégé: Int J Drug Policy
Pays: Netherlands
ID NLM: 9014759
Informations de publication
Date de publication:
04 2020
04 2020
Historique:
received:
02
01
2020
revised:
16
02
2020
accepted:
23
02
2020
pubmed:
9
3
2020
medline:
29
7
2021
entrez:
9
3
2020
Statut:
ppublish
Résumé
Injection drug use (IDU) remains a significant public health problem. IDU has been associated closely with the opioid crisis; driving overdose, HIV, and Hepatitis C (HCV) infection nationwide. Syringe services programs (SSPs) remain pivotal evidence-based interventions to reduce harm and engage subgroups of people who inject drugs (PWID). This study aims to provide policy considerations from the IDEA SSP, the first legal SSP in the state of Florida. We performed a latent class analysis on patterns of substance use among participants (N = 982) newly enrolled in a syringe services program (SSP). Associations between classes of substance use and sociodemographic variables, risky injection and sex behaviors, HIV/HCV status and syringe coverage were analyzed using the R3STEP and BCH 3-step procedures in latent class regression. We found a three-class solution: Heroin-Dominant class (73.9%), Methamphetamine-Dominant class (9.5%) and Heroin/Cocaine class (16.6%). Compared to Heroin-Dominant class, the Heroin/Cocaine class were more likely to report homelessness, sharing works, unprotected sex, public injection, and to be HCV positive. Compared to both Heroin-Dominant and Heroin/Cocaine classes, the Methamphetamine-Dominant class were more likely to be male, Hispanic, gay or bisexual orientation, HIV positive, to report unprotected sex and sex with PWID. In addition, the lowest and highest syringe coverage were among those in the Heroin/Cocaine and Methamphetamine-Dominant classes, respectively. Existing interventions among this population to mitigate infectious disease risk, such as SSPs, can be a used to engage differing PWID populations. However, multi-component, targeted preventive interventions and need-based syringe distribution policies are required to further reduce HIV and HCV risk among various PWID populations.
Identifiants
pubmed: 32146348
pii: S0955-3959(20)30057-8
doi: 10.1016/j.drugpo.2020.102716
pmc: PMC7302981
mid: NIHMS1574841
pii:
doi:
Substances chimiques
Pharmaceutical Preparations
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
102716Subventions
Organisme : NCI NIH HHS
ID : P30 CA240139
Pays : United States
Organisme : NIMH NIH HHS
ID : P30 MH116867
Pays : United States
Organisme : NIDA NIH HHS
ID : R01 DA045713
Pays : United States
Organisme : NIDA NIH HHS
ID : UG1 DA013720
Pays : United States
Informations de copyright
Copyright © 2020 The Authors. Published by Elsevier B.V. All rights reserved.
Références
Subst Use Misuse. 2015;50(10):1351-9
pubmed: 26444185
J Psychiatry Neurosci. 2004 Jan;29(1):40-7
pubmed: 14719049
Drug Alcohol Depend. 2011 Nov 1;118(2-3):237-43
pubmed: 21530105
Int J Drug Policy. 2018 Jul;57:25-31
pubmed: 29660732
AIDS Educ Prev. 2019 Aug;31(4):344-362
pubmed: 31361518
Int J Drug Policy. 2020 Mar;77:102663
pubmed: 31981949
Drug Alcohol Depend. 2012 May 1;122(3):220-7
pubmed: 22030276
Drug Alcohol Depend. 2007 Jul 10;89(2-3):214-22
pubmed: 17280802
J Urban Health. 2010 May;87(3):480-5
pubmed: 20101468
Drug Alcohol Depend. 2013 Oct 1;132(3):441-8
pubmed: 23562370
BMC Public Health. 2017 Apr 11;17(1):309
pubmed: 28399843
J Biomed Inform. 2009 Apr;42(2):377-81
pubmed: 18929686
Drug Alcohol Depend. 2010 Aug 1;110(3):254-8
pubmed: 20456875
Int J Drug Policy. 2020 Feb;76:102642
pubmed: 31918401
Drug Alcohol Depend. 2016 Dec 01;169:171-179
pubmed: 27837708
Psychol Methods. 2012 Jun;17(2):228-43
pubmed: 22309957
Drug Alcohol Depend. 2007 Apr 17;88(1):1-8
pubmed: 17049753
Int J Drug Policy. 2007 Jan;18(1):27-36
pubmed: 17689341
Drug Alcohol Rev. 2018 Jan;37(1):128-136
pubmed: 28337798
AIDS Behav. 2020 Jan;24(1):246-256
pubmed: 31555932
Drug Alcohol Depend. 2001 May 1;62(3):225-30
pubmed: 11295327
EBioMedicine. 2018 Nov;37:374-381
pubmed: 30448155
Harm Reduct J. 2015 Jun 02;12:16
pubmed: 26032673
Drug Alcohol Depend. 2019 Sep 1;202:13-17
pubmed: 31280002
Harm Reduct J. 2019 Jan 23;16(1):7
pubmed: 30674334
AIDS Behav. 2014 Apr;18 Suppl 3:276-83
pubmed: 24510363
Drug Alcohol Depend. 2007 Jun 15;89(1):1-12
pubmed: 17174481
AIDS. 2016 Feb 20;30(4):627-34
pubmed: 26558725
Addiction. 2015 Apr;110(4):572-84
pubmed: 25582153
Med Care. 2015 Apr;53(4):293-301
pubmed: 25710311
N Engl J Med. 2016 Jul 21;375(3):229-39
pubmed: 27468059
Am J Public Health. 2018 Feb;108(2):175-181
pubmed: 29267061
MMWR Morb Mortal Wkly Rep. 2019 Mar 15;68(10):253-254
pubmed: 30870405
Am J Public Health. 2010 Aug;100(8):1449-53
pubmed: 20558797
AIDS Behav. 2018 Apr;22(4):1329-1340
pubmed: 28699018
MMWR Morb Mortal Wkly Rep. 2015 May 8;64(17):453-8
pubmed: 25950251
Int J Drug Policy. 2018 Mar;53:96-105
pubmed: 29306786
MMWR Morb Mortal Wkly Rep. 2019 Apr 19;68(15):344-349
pubmed: 30998671
JAMA Netw Open. 2018 Dec 7;1(8):e186371
pubmed: 30646319
J Acquir Immune Defic Syndr. 2014 Aug 15;66 Suppl 3:S319-28
pubmed: 25007203
Drug Alcohol Depend. 2015 Sep 1;154:283-6
pubmed: 26143300
Am J Public Health. 2020 Jan;110(1):37-44
pubmed: 31725317
Drug Alcohol Depend. 2015 Jul 1;152:272-6
pubmed: 25977204